The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Combinatorial Strategies for the Induction of Immunogenic Cell Death
Open accessAbstract
The term "immunogenic cell death" (ICD) is commonly employed to indicate a peculiar instance of regulated cell death (RCD) that engages the adaptive arm of the immune system. The inoculation of cancer cells undergoing ICD into immunocompetent animals elicits a specific immune response associated with the establishment of immunological memory. Only a few agents are intrinsically endowed with the ability to trigger ICD. These include a few chemotherapeutics that are routinely employed in the clinic, like doxorubicin, mitoxantrone, oxaliplatin, and cyclophosphamide, as well as some agents that have not yet been approved for use in humans. Accumulating clinical data indicate that the activation of adaptive immune responses against dying cancer cells is associated with improved disease outcome in patients affected by various neoplasms. Thus, novel therapeutic regimens that trigger ICD are urgently awaited. Here, we discuss current combinatorial approaches to convert otherwise non-immunogenic instances of RCD into bona fide ICD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Improvement of chemotherapeutic drug efficacy by endoplasmic reticulum stress
Mihailidou, C., Chatzistamou, I., Papavassiliou, A. G., & Kiaris, H. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0019 · Cited by 38
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal
Ndiaye, M., Lespez, L., Tribolo, C., Rassé, M., Hadjas, I., Davidoux, S., Huysecom, É., & Douze, K. (2024) · Monash University Research Portal (Monash University) · doi:10.3929/ethz-b-000667478 · Cited by 23,868
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Accumulating clinical evidence indicates that the (re-)activation of a proficient immune response against malignant cells is associated with improved disease outcome in patients affected by a wide panel of neoplasms (64–68), in particular when malignant lesions are highly infiltrated by immune effector cells prior to…”
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221
The unfolded protein response: controlling cell fate decisions under ER stress and beyond
Hetz, C. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3270 · Cited by 4,093
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399
Self-citationImmunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationRegulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Self-citationType I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Self-citationHigh-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
Lotze, M. T., & Tracey, K. J. (2005) · Nature Reviews Immunology · doi:10.1038/nri1594 · Cited by 2,487
Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.96 · Cited by 2,421
Self-citationDrug delivery with carbon nanotubes for in vivo cancer treatment
Liu, Z., Chen, K., Davis, C. R., Sherlock, S. P., Cao, Q., Chen, X. S., & Dai, H. (2008) · PubMed · doi:10.48550/arxiv.0808.2070 · Cited by 2,286
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationRobert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance
Elliott, M. R., Chekeni, F. B., Trampont, P. C., Lazarowski, E. R., Kadl, A., Walk, S. F., Park, D., Woodson, R. I., Ostankovich, M., Sharma, P., et al. (2009) · Nature · doi:10.1038/nature08296 · Cited by 1,654
Cancer Research Communications
(2021) · doi:10.1158/1078-0432 · Cited by 1,532
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Self-citationAutophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Self-citationMitochondria and the Autophagy–Inflammation–Cell Death Axis in Organismal Aging
Green, D. R., Galluzzi, L., & Kroemer, G. (2011) · Science · doi:10.1126/science.1201940 · Cited by 1,245 · cited 1×
“Second, some malignant cells bear genetic or epigenetic defects that affect the molecular machinery for autophagy (122, 123).”
Self-citationAutophagy in malignant transformation and cancer progression
Galluzzi, L., Pietrocola, F., Bravo‐San Pedro, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D. A., Karantza, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490784 · Cited by 1,182
Self-citationImmunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Self-citationCancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 9×
“Whereas the role of type I IFN in the regulation of innate and adaptive immune responses is well known (128, 129), type I IFN signaling in malignant cells has been identified as a requirement for (anthracycline-induced) ICD only recently (51).”
InfluentialSelf-citationEssential versus accessory aspects of cell death: recommendations of the NCCD 2015
Galluzzi, L., Bravo-San Pedro, J. M., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Alnemri, E. S., Altucci, L., Andrews, D., Annicchiarico-Petruzzelli, M., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.137 · Cited by 1,002
Self-citationZitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Self-citationMechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death
Panaretakis, T., Kepp, O., Brockmeier, U., Tesniere, A., Bjorklund, A., Chapman, D. C., Durchschlag, M., Joza, N., Pierron, G., van Endert, P., et al. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.1 · Cited by 848
Self-citationConsensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Self-citationA novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
Garg, A. D., Krysko, D. V., Verfaillie, T., Kaczmarek, A., Ferreira, G. B., Marysael, T., Rubio, N., Firczuk, M., Mathieu, C., Roebroek, A. J. M., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2011.497 · Cited by 800
Mitochondria: master regulators of danger signalling
Galluzzi, L., Kepp, O., & Kroemer, G. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3479 · Cited by 733
Self-citationMetabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
Self-citationMa, Y., Adjemian, S., Mattarollo, S. R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J. P., Hannani, D., Duret, H., Steegh, K., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.03.003 · Cited by 699
Self-citationThe secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Self-citationRadiation fosters dose-dependent and chemotherapy-induced immunogenic cell death
Golden, E. B., Frances, D., Pellicciotta, I., Demaria, S., Helen Barcellos-Hoff, M., & Formenti, S. C. (2014) · OncoImmunology · doi:10.4161/onci.28518 · Cited by 624
Molecular mechanisms of ATP secretion during immunogenic cell death
Martins, I., Wang, Y., Michaud, M., Ma, Y., Sukkurwala, A. Q., Shen, S., Kepp, O., Métivier, D., Galluzzi, L., Perfettini, J.-L., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.75 · Cited by 563 · cited 1×
“course of stress responses, resulting in limited ATP secretion during death (124).”
Self-citationDecoding Cell Death Signals in Inflammation and Immunity
Zitvogel, L., Kepp, O., & Kroemer, G. (2010) · Cell · doi:10.1016/j.cell.2010.02.015 · Cited by 558 · cited 1×
“According to accepted models, ICD relies on the establishment of adaptive stress responses that promote the spatiotemporally coordinated emission of endogenous danger signals from dying cells (44, 45).”
Self-citationImmunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation
Garg, A. D., Nowis, D., Golab, J., Vandenabeele, P., Krysko, D. V., & Agostinis, P. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.08.003 · Cited by 496
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Self-citationRadiotherapy and Immunogenic Cell Death
Golden, E. B., & Apetoh, L. (2015) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2014.07.005 · Cited by 463
MacLeod (2008) · Bristol Research (University of Bristol) · doi:10.4049/jimmunol · Cited by 448
Autophagy and cellular immune responses
Ma, Y., Galluzzi, L., Zitvogel, L., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.017 · Cited by 447
Self-citationAn Immunosurveillance Mechanism Controls Cancer Cell Ploidy
Senovilla, L., Vitale, I., Martins, I., Tailler, M., Pailleret, C., Michaud, M., Galluzzi, L., Adjemian, S., Kepp, O., Niso-Santano, M., et al. (2012) · Science · doi:10.1126/science.1224922 · Cited by 436
Self-citationCardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death
Menger, L., Vacchelli, E., Adjemian, S., Martins, I., Ma, Y., Shen, S., Yamazaki, T., Sukkurwala, A. Q., Michaud, M., Mignot, G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003807 · Cited by 423
Self-citationMartins, I., Kepp, O., Schlemmer, F., Adjemian, S., Tailler, M., Shen, S., Michaud, M., Menger, L., Gdoura, A., Tajeddine, N., et al. (2011) · Oncogene · doi:10.1038/onc.2010.500 · Cited by 414
Self-citationMonoclonal Antibodies for Cancer Therapy
(2012) · SpringerReference · doi:10.1007/springerreference_303431 · Cited by 393
Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response
Fucikova, J., Kralikova, P., Fialova, A., Brtnicky, T., Rob, L., Bartunkova, J., & Špíšek, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0950 · Cited by 392
Self-citationSpisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388
Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates
Fridman, W. H., Galon, J., Pagès, F., Tartour, E., Sautès-Fridman, C., & Kroemer, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1316 · Cited by 380
Self-citationJournal of Experimental Medicine
(2019) · The Journal of Experimental Medicine · doi:10.1084/jem · Cited by 366
Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362
Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
Anitei, M.-G., Zeitoun, G., Mlecnik, B., Marliot, F., Haicheur, N., Todosi, A.-M., Kirilovsky, A., Lagorce, C., Bindea, G., Ferariu, D., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2830 · Cited by 358
The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death
Panaretakis, T., Joza, N., Modjtahedi, N., Tesniere, A., Vitale, I., Durchschlag, M., Fimia, G. M., Kepp, O., Piacentini, M., Froehlich, K.-U., et al. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.67 · Cited by 344
Self-citationContribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
Ma, Y., Aymeric, L., Locher, C., Mattarollo, S. R., Delahaye, N. F., Pereira, P., Boucontet, L., Apetoh, L., Ghiringhelli, F., Casares, N., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100269 · Cited by 337
Self-citationROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death
Garg, A. D., Dudek, A. M., Ferreira, G. B., Verfaillie, T., Vandenabeele, P., Krysko, D. V., Mathieu, C., & Agostinis, P. (2013) · Autophagy · doi:10.4161/auto.25399 · Cited by 305
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
Sistigu, A., Viaud, S., Chaput, N., Bracci, L., Proietti, E., & Zitvogel, L. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0245-0 · Cited by 305
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy
Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 297
Self-citationMany faces of DAMPs in cancer therapy
Krysko, O., Løve Aaes, T., Bachert, C., Vandenabeele, P., & Krysko, D. V. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.156 · Cited by 296
Garg, A. D., Krysko, D. V., Vandenabeele, P., & Agostinis, P. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1184-2 · Cited by 292
Hodge, J. W., Garnett, C. T., Farsaci, B., Palena, C., Tsang, K., Ferrone, S., & Gameiro, S. R. (2013) · International Journal of Cancer · doi:10.1002/ijc.28070 · Cited by 281
Chemotherapy induces ATP release from tumor cells
Martins, I., Tesniere, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J.-L., Zitvogel, L., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.22.10026 · Cited by 278
Self-citationGarg, A. D., & Agostinis, P. (2014) · Photochemical & Photobiological Sciences · doi:10.1039/c3pp50333j · Cited by 276
Korbelik, M., Sun, J., & Cecic, I. (2005) · Cancer Research · doi:10.1158/0008-5472.1018.65.3 · Cited by 273
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
Self-citationDefective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists
Yamazaki, T., Hannani, D., Poirier-Colame, V, Ladoire, S., Locher, C., Sistigu, A., Prada, N., Adjemian, S., Catani, J. P., Freudenberg, M., et al. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.72 · Cited by 262
Self-citationMolecular mechanisms of regulated necrosis
Galluzzi, L., Kepp, O., Krautwald, S., Kroemer, G., & Linkermann, A. (2014) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2014.02.006 · Cited by 258
Self-citationTrial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Self-citationInducers of immunogenic cancer cell death
Dudek, A. M., Garg, A. D., Krysko, D. V., De Ruysscher, D., & Agostinis, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.005 · Cited by 250
Organelle-specific initiation of cell death
Galluzzi, L., Bravo-San Pedro, J. M., & Kroemer, G. (2014) · Nature Cell Biology · doi:10.1038/ncb3005 · Cited by 239
Self-citationTrial watch: Prognostic and predictive value of the immune infiltrate in cancer
Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A., Fridman, W. H., Sautès-Fridman, C., Ma, Y., Tartour, E., Zitvogel, L., et al. (2012) · OncoImmunology · doi:10.4161/onci.22009 · Cited by 235
Self-citationCrosstalk between ER stress and immunogenic cell death
Kepp, O., Menger, L., Vacchelli, E., Locher, C., Adjemian, S., Yamazaki, T., Martins, I., Sukkurwala, A. Q., Michaud, M., Senovilla, L., et al. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.05.001 · Cited by 233
Self-citationKoks, C. A., Garg, A. D., Ehrhardt, M., Riva, M., Vandenberk, L., Boon, L., Vleeschouwer, S. D., Agostinis, P., Graf, N., & Van Gool, S. W. (2015) · International Journal of Cancer · doi:10.1002/ijc.29202 · Cited by 206
Measles virus causes immunogenic cell death in human melanoma
Donnelly, O. G., Errington-Mais, F., Steele, L., Hadac, E., Jennings, V, Scott, K., Peach, H., Phillips, R. M., Bond, J., Pandha, H., et al. (2013) · Gene Therapy · doi:10.1038/gt.2011.205 · Cited by 187
Trial Watch: Toll-like receptor agonists for cancer therapy
Vacchelli, E., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25238 · Cited by 180
Self-citationTrial Watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27878 · Cited by 173
Self-citationVural, D. F., Cebesoy, S., & Karakaş, M. F. (2013) · Journal of Entomology and Zoology Studies · Cited by 172
High hydrostatic pressure induces immunogenic cell death in human tumor cells
Fucikova, J., Moserova, I., Truxova, I., Hermanova, I., Vancurova, I., Partlova, S., Fialova, A., Sojka, L., Cartron, P., Houska, M., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28766 · Cited by 170
Self-citationLiikanen, I., Ahtiainen, L., Hirvinen, M. L., Bramante, S., Cerullo, V., Nokisalmi, P., Hemminki, O., Diaconu, I., Pesonen, S., Koski, A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.51 · Cited by 165
Trial Watch: Monoclonal antibodies in cancer therapy
Galluzzi, L., Vacchelli, E., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zucman‐Rossi, J., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17938 · Cited by 152
Self-citationZappasodi, R., Pupa, S. M., Ghedini, G. C., Bongarzone, I., Magni, M., Cabras, A. D., Colombo, M. P., Carlo‐Stella, C., Gianni, A. M., & Nicola, M. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1825 · Cited by 150
Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer
Galluzzi, L., Vitale, I., Senovilla, L., Olaussen, K. A., Pinna, G., Eisenberg, T., Goubar, A., Martins, I., Michels, J., Kratassiouk, G., et al. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.06.017 · Cited by 150
Self-citationScreening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set
Sukkurwala, A. Q., Adjemian, S., Senovilla, L., Michaud, M., Spaggiari, S., Vacchelli, E., Baracco, E. E., Galluzzi, L., Zitvogel, L., Kepp, O., et al. (2014) · OncoImmunology · doi:10.4161/onci.28473 · Cited by 144
Self-citationZhao, T., Ren, H., Jia, L., Chen, J., Xin, W., Yan, F., Li, J., Wang, X., Gao, S., Qian, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2948 · Cited by 142
Enlightening the impact of immunogenic cell death in photodynamic cancer therapy
Galluzzi, L., Kepp, O., & Kroemer, G. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.2 · Cited by 142
Self-citationTrial watch: Cardiac glycosides and cancer therapy
Menger, L., Vacchelli, E., Kepp, O., Eggermont, A. M. M., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23082 · Cited by 141
Self-citationImmunogenic cell death in radiation therapy
Galluzzi, L., Kepp, O., & Kroemer, G. (2013) · OncoImmunology · doi:10.4161/onci.26536 · Cited by 138
Self-citationWémeau, M., Kepp, O., Tesnière, A., Panaretakis, T., Flament, C., de Botton, S., Zitvogel, L., Kroemer, G., & Chaput, N. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.82 · Cited by 135
Self-citationBugaut, H., Bruchard, M., Berger, H., Dérangère, V., Odoul, L., Euvrard, R., Ladoire, S., Chalmin, F., Végran, F., Rébé, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065181 · Cited by 130
eIF2α phosphorylation as a biomarker of immunogenic cell death
Kepp, O., Semeraro, M., Pedro, J. M. B., Bloy, N., Buqué, A., Huang, X., Zhou, H., Senovilla, L., Kroemer, G., & Galluzzi, L. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.02.004 · Cited by 129
Self-citationCancer immunogenicity, danger signals, and DAMPs: What, when, and how?
Garg, A. D., Dudek, A. M., & Agostinis, P. (2013) · BioFactors · doi:10.1002/biof.1125 · Cited by 128
Korbelik, M., Zhang, W., & Merchant, S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1047-x · Cited by 123
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy
Aranda, F., Vacchelli, E., Eggermont, A. M. M., Galon, J., Fridman, W. H., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27297 · Cited by 119
Self-citationCombination of glycolysis inhibition with chemotherapy results in an antitumor immune response
Bénéteau, M., Zunino, B., Jacquin, M. A., Meynet, O., Chiche, J., Pradelli, L. A., Marchetti, S., Cornille, A., Carlès, M., & Ricci, J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206360109 · Cited by 113
Trial Watch: DNA vaccines for cancer therapy
Pol, J. G., Bloy, N., Obrist, F., Eggermont, A. M. M., Galon, J., Fridman, W. H., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28185 · Cited by 110
Self-citationHoffmann, J., Vitale, I., Buchmann, B., Galluzzi, L., Schwede, W., Senovilla, L., Skuballa, W., Vivet, S., Lichtner, R. B., Vicencio, J. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0237 · Cited by 110
Self-citationMa, Y., Adjemian, S., Yang, H., Catani, J. P. P., Hannani, D., Martins, I., Michaud, M., Kepp, O., Sukkurwala, A. Q., Vacchelli, E., et al. (2013) · OncoImmunology · doi:10.4161/onci.24568 · Cited by 104
Self-citationDudek-Perić, A. M., Ferreira, G. B., Muchowicz, A., Wouters, J., Prada, N., Martin, S., Kiviluoto, S., Winiarska, M., Boon, L., Mathieu, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2089 · Cited by 104
Reticulon 1‐C/neuroendocrine‐specific protein‐C interacts with SNARE proteins
Steiner, P., Kulangara, K., Sarria, J. ‐. F., Glauser, L., Regazzi, R., & Hirling, H. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02345.x · Cited by 101
Trial watch: Monoclonal antibodies in cancer therapy
Vacchelli, E., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2012) · OncoImmunology · doi:10.4161/onci.22789 · Cited by 101
Self-citationTrial Watch: Anticancer radioimmunotherapy
Vacchelli, E., Vitale, I., Tartour, É., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25595 · Cited by 100
Self-citationTressler, A. B., Peñuela, S., Laird, D. W., & Dubyak, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.590240 · Cited by 97
Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer
Aranda, F., Bloy, N., Pesquet, J., Petit, B., Chaba, K., Sauvat, A., Kepp, O., Khadra, N., Enot, D., Pfirschke, C., et al. (2015) · Oncogene · doi:10.1038/onc.2014.234 · Cited by 89
Self-citationImmunogenic cell death inducers as anticancer agents
Kepp, O., Senovilla, L., & Kroemer, G. (2014) · Oncotarget · doi:10.18632/oncotarget.2266 · Cited by 88
Self-citationImmune Mechanism of the Antitumor Effects Generated by Bortezomib
Chang, C.-L., Hsu, Y.-T., Wu, C.-C., Yang, Y., Wang, C., Wu, T.-Q., & Hung, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103826 · Cited by 87
Cirone, M., Renzo, L. D., Lotti, L. V., Conte, V., Trivedi, P., Santarelli, R., Gonnella, R., Frati, L., & Faggioni, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031732 · Cited by 86
Trial Watch: Toll-like receptor agonists in oncological indications
Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Cremer, I., ter Meulen, J. H., Zitvogel, L., Kroemer, G., et al. (2014) · OncoImmunology · doi:10.4161/onci.29179 · Cited by 85
Self-citationAn autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy
Michaud, M., Xie, X., Pedro, J. M. B., Zitvogel, L., White, E., & Kroemer, G. (2014) · OncoImmunology · doi:10.4161/21624011.2014.944047 · Cited by 85
Self-citationStoetzer, O., Fersching, D., Salat, C., Steinkohl, O., Gabka, C., Hamann, U., Braun, M., Feller, A., Heinemann, V., Siegele, B., et al. (2013) · Tumor Biology · doi:10.1007/s13277-012-0513-1 · Cited by 82
Rubner, Y., Muth, C., Strnad, A. R., Derer, A., Sieber, R., Buslei, R., Frey, B., Fietkau, R., & Gaipl, U. S. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-89 · Cited by 76
Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
Michaud, M., Sukkurwala, A. Q., Martins, I., Shen, S., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.19070 · Cited by 74
Self-citationWorkenhe, S. T., Pol, J. G., Lichty, B. D., Cummings, D. T., & Mossman, K. L. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0059-t · Cited by 73
Select forms of tumor cell apoptosis induce dendritic cell maturation
Demaria, S., Santori, F. R., Ng, B., Liebes, L., Formenti, S. C., & Vukmanović, S. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0804478 · Cited by 71
Immunomodulatory therapy for melanoma: Ipilimumab and beyond
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2013) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2012.08.006 · Cited by 70
Lu, X., Ding, Z., Cao, Y., Liu, C., Habtetsion, T. G., Yu, M., Lemos, H. D. P., Salman, H., Xu, H., Mellor, A. L., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401894 · Cited by 67
Chen, X., Yang, Y.-A., Zhou, Q., Weiss, J. M., Howard, O. Z., McPherson, J. M., Wakefield, L. M., & Oppenheim, J. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085398 · Cited by 62
Trial Watch: Radioimmunotherapy for oncological indications
Bloy, N., Pol, J. G., Manic, G., Vitale, I., Eggermont, A. M. M., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954929 · Cited by 56
Self-citationDisruption of the PP1/GADD34 complex induces calreticulin exposure
Kepp, O., Galluzzi, L., Giordanetto, F., Tesnière, A., Vitale, I., Martins, I., Schlemmer, F., Adjemian, S., Zitvogel, L., & Kroemer, G. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10191 · Cited by 56
Self-citationMartin, S., Dudek-Perić, A. M., Maes, H., Garg, A. D., Gabrysiak, M., Demirsoy, S., Swinnen, J. V., & Agostinis, P. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.003 · Cited by 54
Chemo-Immunotherapy with Oxaliplatin and Interleukin-7 Inhibits Colon Cancer Metastasis in Mice
Gou, H., Huang, J., Shi, H., Chen, X.-C., & Wang, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085789 · Cited by 52
Cirone, M., Garufi, A., Renzo, L. D., Granato, M., Faggioni, A., & D’Orazi, G. (2013) · OncoImmunology · doi:10.4161/onci.26198 · Cited by 52
Activation of dendritic cells by tumor cell death
Cirone, M., Renzo, L. D., Lotti, L. V., Conte, V., Trivedi, P., Santarelli, R., Gonnella, R., Frati, L., & Faggioni, A. (2012) · OncoImmunology · doi:10.4161/onci.20428 · Cited by 50
Frey, B., Stache, C., Rubner, Y., Werthmöller, N., Schulz, K., Sieber, R., Semrau, S., Rödel, F., Fietkau, R., & Gaipl, U. S. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.693547 · Cited by 48
Srivastava, A. K., Dinc, G., Sharma, R. K., Yolcu, E. S., Zhao, H., & Shirwan, H. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1768-a · Cited by 43
Expression and Effects of High-Mobility Group Box 1 in Cervical Cancer
Pang, X., Zhang, Y., Wei, H., Zhang, J., Luo, Q., Huang, C., & Zhang, S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15058699 · Cited by 43
Garg, A. D., Dudek, A. M., & Agostinis, P. (2013) · OncoImmunology · doi:10.4161/onci.26260 · Cited by 42
Novel immune checkpoint blocker approved for the treatment of advanced melanoma
Galluzzi, L., Kroemer, G., & Eggermont, A. M. M. (2014) · OncoImmunology · doi:10.4161/21624011.2014.967147 · Cited by 39
Self-citationThe key role of calreticulin in immunomodulation induced by chemotherapeutic agents
Yamamura, Y., Tsuchikawa, T., Miyauchi, K., et al. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0719-x · Cited by 36
Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress
Michaud, M., Sukkurwala, A. Q., Sano, F. D., Zitvogel, L., Kepp, O., & Kroemer, G. (2014) · OncoImmunology · doi:10.4161/onci.28276 · Cited by 36
Self-citationCurrent trends of anticancer immunochemotherapy
Vacchelli, E., Prada, N., Kepp, O., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25396 · Cited by 32
Self-citationTherapeutic Implications of Immunogenic Cell Death in Human Cancer
Palombo, F., Focaccetti, C., & Barnaba, V. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00503 · Cited by 28
Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
Workenhe, S. T., & Mossman, K. L. (2013) · OncoImmunology · doi:10.4161/onci.27138 · Cited by 27
Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells
Pellicciotta, I., Yang, C. H., Goldberg, G. L., & Shahabi, S. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.05.007 · Cited by 25
Vitamin B6 improves the immunogenicity of cisplatin-induced cell death
Aranda, F., Bloy, N., Galluzzi, L., Kroemer, G., & Senovilla, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955685 · Cited by 25
Self-citationSmart therapeutic strategies in immuno-oncology
Eggermont, A. M. M., & Robert, C. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.36 · Cited by 24
The Janus face of cyclophosphamide
Ziccheddu, G., Proietti, E., & Moschella, F. (2013) · OncoImmunology · doi:10.4161/onci.25789 · Cited by 23
Wang, W., Qin, S., & Zhao, L. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.10.026 · Cited by 17
The role of ifosfamide and etoposide in Ewing sarcoma
DuBois, S. G., & Grier, H. E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.25 · Cited by 9
(2015) · OncoImmunology · doi:10.4161/onci · Cited by 6
Cited by
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Self-citationThe biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Self-citationImmunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types?
Rosales, C. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00113 · Cited by 1,334
Metadata
- Authors
- Bezu, L., Gomes-de-Silva, L. C., Dewitte, H., Breckpot, K., Fucikova, J., Spisek, R., Galluzzi, L., Kepp, O., & Kroemer, G.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2015-04-24
- Volume
- 6
- Pages
- 187-187
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2036431563
- Cited by
- 390
- References
- 146
- FWCI
- 15.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.